Navigation Links
Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease
Date:10/2/2009

," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential goals, progress, timing and final results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical studies indicate that the product candidates are unsafe or ineffective; the potential that clinical studies could be delayed because we identify serious side effects or other safety issues; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. Additionally, with respect to statements regarding projections of the Company's cash position and expected use of cash during 2009, actual results may differ based on market factors, the Company's ability to execute its operational and budget plans, and its achievement of milestones and receipt of milestone payments and reimbursements from Shire. Additionally, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-loo
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc.
2. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
3. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured on NewsWatch ... products available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, ... versatile smart light bulbs on the market. , According to the U.S. Department of ...
(Date:7/2/2015)... PEACHTREE CITY, GA (PRWEB) , ... July 02, ... ... or field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the ... physicians, fitness experts and athletic trainers. Their significant popularity has inspired four new, ...
(Date:7/2/2015)... ... , ... Six months ahead of his 80th birthday, Don Stevenson has reached ... for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington State ... mid-September. He left Glasgow, Mont. yesterday morning and is making his way to Wolf ...
(Date:7/2/2015)... Diego, CA (PRWEB) , ... July 02, 2015 , ... ... and a passion for social fitness. Built to function as a lifestyle community, Active ... giving them the opportunity to network, meet, and participate in discussions or group events. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... - pipeline review 2015” provides comprehensive information on the pipeline products with ... on negative pressure wound therapy (NPWT) with 22 market data tables and ...
Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4
... to the health threat posed by Americans, over-consumption of sodium, ... Public Health (HSPH) and The Culinary Institute of America (CIA) ... effectiveand that maximize the enjoyment people derive from food. ... sodium reduction as a critical public health priority, much as ...
... ,e-visit, using images sent via Internet, study finds , ... who had online follow-up visits with their dermatologist had ... a new study finds. , The study included 121 ... follow-up visits or four in-office visits. Every six weeks, ...
... ... Energy without the stomach issues. The Company chose four test markets to evaluate adoption ... ... Energy ™ patches are newly released to the retail market. Many health conscious adults ...
... University of Illinois have identified a potential drug target ... is embedded in the membrane of neurons and other ... activates this receptor, sparking increased activity in the affected ... The new findings appear in the FASEB Journal ...
... ... Will Participate – Savings and Valuable Incentives Are Still Available , ... (Vocus) April 20, 2010 -- Toll Brothers, the ... at communities nationwide from April 24 until May 2. With the slight rise in interest ...
... ... babies. , ... April 20, 2010 -- Building on 175 years of expertise in the care for mothers ... new , , , , ,ePhilanthropy venture dedicated to supporting healthy moms, pregnancies and babies. ...
Cached Medicine News:Health News:Experts call for accelerated national sodium reduction initiatives 2Health News:Experts call for accelerated national sodium reduction initiatives 3Health News:Experts call for accelerated national sodium reduction initiatives 4Health News:Acne Patients Happy With Online Follow-Up Care 2Health News:Peoria and Baltimore Serve as Test Markets for New Spot On Energy Product 2Health News:Team finds promising new drug target for Alzheimer's disease 2Health News:Team finds promising new drug target for Alzheimer's disease 3Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 2Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 3Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 4Health News:Brigham and Women's Hospital Launches Stork Fund 2Health News:Brigham and Women's Hospital Launches Stork Fund 3
(Date:7/2/2015)...   , July 2, 2015 BGI ... Hong Kong has been accredited ... Kong facility is the first clinical next-generation-sequencing laboratory to ... , meeting the highest standard in clinical laboratory practices. Complementary ... 11 compliant laboratory process, and multiple ISO certifications, the ...
(Date:7/2/2015)...   Wilson Therapeutics AB , a privately-held biopharmaceutical ... its board of directors. The appointment was approved by ... 30. "We are delighted to welcome Hans ... , CEO of Wilson Therapeutics. "Hans brings significant global ... to his contributions to the Company." Hans ...
(Date:7/1/2015)... 1, 2015 The Coalition of State ... and regional professional rheumatology societies, today released the ... explored perceptions of biosimilars and the potential impact ... Biosimilars are medicines that are highly similar, ... notably different from generic medications in that it ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Wilson Therapeutics Appoints Hans Schikan to its Board of Directors 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2
Protein-to-creatinine ratio is key to earlier detection of Kidney Disease...
... Your basic entry to ... Urine Analyzer delivers an affordable, ... test strip evaluation. With fundamental, ... Urine Analyzer keeps physician office ...
... The Clinitek 50 analyzer is an ... smaller laboratories the reliability and consistency ... better, more efficient way to obtain ... settings demand an economy of motion ...
... dual pressure sensor catheters incorporate ... slow-speed injection/guide wire, or high-speed ... for high-speed injection has two ... and an open-end pigtail extension ...
Medicine Products: